Amgen Vectibix Approved For Metastatic Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The first entirely human anti-EGFR antibody will launch in early or mid-October.
You may also be interested in...
EMEA Recommends Conditional European Marketing Authorization For Amgen's Vectibix
Company requested a re-examination of its application for colorectal cancer after EMEA refused marketing approval in May.
EMEA Recommends Conditional European Marketing Authorization For Amgen's Vectibix
Company requested a re-examination of its application for colorectal cancer after EMEA refused marketing approval in May.
Erbitux Gets Priority Review For Third-Line Colorectal Cancer Claim
The sBLA, which includes studies showing an overall survival benefit, has an early October user fee date.